{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Menz BD"],"funding":["Tour de Cure","Hospital Research Foundation","National Health and Medical Research Council"],"pagination":["2135-2145"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12439079"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["157(10)"],"pubmed_abstract":["Researchers at the EORTC recently recommended clinical thresholds for the QLQ-C30 to facilitate actionable insights in clinical practice. We evaluate the distribution of these thresholds and associations with outcomes in breast cancer. Data were pooled from two early-stage and six advanced-stage breast cancer trials. EORTC thresholds were applied to available QLQ-C30 data to identify clinically important PRO domains. Associations between the number of clinically important PRO domains at baseline with overall survival (OS), invasive-disease-free survival (IDFS), progression-free survival (PFS), grade ≥3 adverse events (AEs), and serious AEs were evaluated using Cox-regression. Data from 8544 breast cancer patients, of whom 2428 (41%) of the 5893 early-stage and 1486 (56%) of the 2651 advanc"],"journal":["International journal of cancer"],"pubmed_title":["Patient-reported outcome thresholds and their associations with survival, adverse events, and quality of life in a pooled analysis of breast cancer trials."],"pmcid":["PMC12439079"],"funding_grant_id":["2023‐S‐DTFA‐005","APP2030913","2023-S-DTFA-005","APP2008119","RSP-117-FY2023","RSP‐117‐FY2023"],"pubmed_authors":["Lyman GH","Menz BD","Hopkins AM","Chan RJ","Shahnam A","Kuderer NM","Sorich MJ","Rowland A","Haseloff M","Rammant E","Ramsey I","Modi ND","Vitry A","McKinnon RA","Abuhelwa AY","Kichenadasse G","Swain SM"],"additional_accession":[]},"is_claimable":false,"name":"Patient-reported outcome thresholds and their associations with survival, adverse events, and quality of life in a pooled analysis of breast cancer trials.","description":"Researchers at the EORTC recently recommended clinical thresholds for the QLQ-C30 to facilitate actionable insights in clinical practice. We evaluate the distribution of these thresholds and associations with outcomes in breast cancer. Data were pooled from two early-stage and six advanced-stage breast cancer trials. EORTC thresholds were applied to available QLQ-C30 data to identify clinically important PRO domains. Associations between the number of clinically important PRO domains at baseline with overall survival (OS), invasive-disease-free survival (IDFS), progression-free survival (PFS), grade ≥3 adverse events (AEs), and serious AEs were evaluated using Cox-regression. Data from 8544 breast cancer patients, of whom 2428 (41%) of the 5893 early-stage and 1486 (56%) of the 2651 advanc","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-06-03T03:02:14.135Z","creation":"2026-04-23T03:13:52.726Z"},"accession":"S-EPMC12439079","cross_references":{"pubmed":["40542609"],"doi":["10.1002/ijc.70020"]}}